PMID- 24001224
OWN - NLM
STAT- MEDLINE
DCOM- 20140915
LR  - 20211203
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 20
IP  - 1
DP  - 2014
TI  - The mTOR signaling pathway is an emerging therapeutic target in multiple myeloma.
PG  - 125-35
AB  - The mammalian target of rapamycin (mTOR) is a PI3K-related serine/threonine 
      kinase and plays a critical role in modulating proliferation, growth, survival, 
      invasion and chemoresistance of multiple myeloma, a malignancy of plasma cells. 
      Since it was identified as the therapeutic target of rapamycin, mTOR has been 
      applied for anti-cancer drug discovery. More and more mTOR inhibitors have been 
      developed and demonstrated with great clinical potentials for multiple myeloma 
      and other cancers. In this review, we highlighted advances in drug discovery 
      targeting the mTOR signaling pathway for the treatment of multiple myeloma with 
      an input from our recent studies.
FAU - Li, Jie
AU  - Li J
FAU - Zhu, Jingyu
AU  - Zhu J
FAU - Cao, Biyin
AU  - Cao B
FAU - Mao, Xinliang
AU  - Mao X
AD  - Laboratory of Targeted Antileukemia Drug Discovery, Cyrus Tang Hematology Center, 
      Soochow University, 199 Ren Ai Road, Room703-507, Suzhou Industrial Park, Suzhou, 
      China 215123. xinliangmao@suda.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Immunosuppressive Agents)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
SB  - IM
MH  - Humans
MH  - Immunosuppressive Agents/chemistry/pharmacology/therapeutic use
MH  - Multiple Myeloma/*drug therapy/metabolism
MH  - *Signal Transduction
MH  - TOR Serine-Threonine Kinases/chemistry/*drug effects/metabolism
EDAT- 2013/09/05 06:00
MHDA- 2014/09/16 06:00
CRDT- 2013/09/05 06:00
PHST- 2013/06/23 00:00 [received]
PHST- 2013/09/02 00:00 [accepted]
PHST- 2013/09/05 06:00 [entrez]
PHST- 2013/09/05 06:00 [pubmed]
PHST- 2014/09/16 06:00 [medline]
AID - CPD-EPUB-55753 [pii]
AID - 10.2174/13816128113199990638 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2014;20(1):125-35. doi: 10.2174/13816128113199990638.